RxDoctor Payments DataLook up a doctor →

Adolfo Sanchez, MD

Family Medicine · Belen, NMNPI 1003117698

Payments from drug & device makers

$7,677in general payments, 2019–2025

Across 466 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$870
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$721
  • Pfizer$611
  • AstraZeneca$558
  • Sanofi-aventis U.S. LLC$549
  • Lilly USA, LLC$492
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,59999%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,677 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$142,686
Medicare patients
377
Services billed
2,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin132$115,193
EliquisApixaban102$105,809
XareltoRivaroxaban96$87,515
JanuviaSitagliptin Phosphate66$78,264
OzempicSemaglutide64$65,577
FarxigaDapagliflozin Propanediol60$53,712
RybelsusSemaglutide20$38,523
Spiriva RespimatTiotropium Bromide61$31,652
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$28,210
TrulicityDulaglutide22$26,894
RexultiBrexpiprazole11$23,765
Tresiba Flextouch U-100Insulin Degludec27$18,244
Soliqua 100-33Insulin Glargine/Lixisenatide18$15,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,108
JanumetSitagliptin Phos/Metformin Hcl14$14,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$269$153,056205 claims
PfizerEliquis$611$105,809102 claims
Novo NordiskOzempic, Rybelsus$216$104,10084 claims
MerckJanuvia, Janumet$71$93,20980 claims
Johnson & JohnsonXarelto$178$87,51596 claims
AstraZenecaFarxiga, Symbicort$558$58,22179 claims
Lilly USA, LLCTrulicity$492$26,89422 claims
Otsuka America Pharmaceutical, Inc.Rexulti$261$23,76511 claims
GSKTrelegy Ellipta, Arnuity Ellipta$108$20,67239 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$549$15,37118 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$27$3,41012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Belen

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →